15 Best Large-Cap Value Stocks to Buy in 2025

Page 10 of 14

5. Eli Lilly and Company (NYSE:LLY)

Analyst Upside as of January 20, 2025: 38%

Number of Hedge Fund Holders: 106

Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company that sells medicines for serious illnesses in 125 countries and has offices in 18. During the third quarter of 2024, the company received product approvals and launched new pipeline data for crucial drugs. The company’s performance and growth trajectory coupled with its diverse portfolio of drugs and medicines contributes to its position on our list. Analysts are also bullish on the stock and their median price target implies an upside of 38% from current levels.

On January 15, Chris Schott, an analyst at JPMorgan, suggested that the Q4 miss puts forward a buying opportunity as LLY is positioned for robust growth in 2025. Schott added that the company’s 2025 sales guidance is driven by its expanded label and growing geographic footprint. As a result, dosage sales of incretins are expected to grow by 60% year-over-year in the first half of 2025. The analyst also added that the Q4 miss is primarily due to an unexpected decline in wholesaler volumes and inventory. He maintained an overweight rating on the stock.

The stock also received a buy rating from Jefferies on January 15 and a buy from Bank of America Securities on January 21, 2025. LLY is positioned for tremendous growth, making it one of the best large-cap value stocks to buy in 2025.

Page 10 of 14